胃肠间质瘤的诊治进展  

The diagnosis and treatment of gastrointestinal stromal tumor

作　　者：付亚如[1] 高天慧[1] 崔瑶[1] 蔡利红[1] 

机构地区：[1]河南省人民医院(郑州大学人民医院)肿瘤科,河南郑州450003

出　　处：《胃肠病学和肝病学杂志》2015年第11期1412-1414,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：胃肠间质瘤（gastrointestinal stromal tumor,GIST）是起源于胃肠道间叶源性的肿瘤,占消化道肿瘤的1%~3%,最好发部位为胃。GIST的发病机制与c-kit或血小板源性生长因子受体α（PDGFRα）的活化突变有关。GIST确诊依靠病理学,治疗上以外科手术和分子靶向药物为主,其预后与肿瘤大小、发生部位、核分裂象等多种因素有关。Gastrointestinal stromal tumor （GIST） is originated from the mesenchymal tissue of gastrointestinal tract, accounting for 1% - 3% of digestive tract tumors, the most common organ that GIST involved is stomach. The pathogen- esis of GIST is related to c-kit or platelet-derived growth factor receptor alpha （PDGFRct） activating mutation. Confirmed diagnosis depends on pathology. The mainly effective treatments include surgery and molecular targeted drugs. The prognosis is correlated with tumor size, the organ that the tumor involved, nucleus mitotic counts and other factors.

关 键 词：GIST C-KIT PDGFRΑ 诊断 手术 靶向药物 

分 类 号：R735[医药卫生—肿瘤]